Aurion Biotech, a spinoff of Seattle eye care company, CorneaGen, has received $120M in funding to help advance cell therapy for corneal endothelial dystrophies, an eye disorder affecting millions.
The round was led by Deerfield Management, with additional contributions from Petrichor Healthcare Capital Management, Flying L Partners, Falcon Vision, Visionary Ventures, and Alcon.
“Our financing speaks volumes about the potential of our cell therapy to transform the lives of millions of people suffering from corneal endothelial dystrophies,” said Aurion Biotech CEO and president, Greg Kunst.